S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Celldex Therapeutics Announces Appointment to Board of Directors|
|Celldex Therapeutics Announces Upcoming Presentations of Rindopepimut Data at 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)|
|Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced Melanoma|
|Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab|
|Celldex Reports Third Quarter 2014 Results|
|Celldex Presents Varlilumab Proof of Concept Data at SITC Annual Meeting 2014|
|Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit|
|Celldex Announces Completion of Enrollment in Phase 3 Study of Rindopepimut in Frontline Glioblastoma|
|Market technicals bend, but don't break (2015/1/13)|
|UPDATE: Major U.S. benchmarks challenge last-ditch support (2015/1/20)|
Click above to view more mutual fund data and stats for cldx - Celldex Therapeutics Inc.